298 related articles for article (PubMed ID: 15679068)
21. Pamidronate treatment of osteogenesis imperfecta--lack of correlation between clinical severity, age at onset of treatment, predicted collagen mutation and treatment response.
Zacharin M; Bateman J
J Pediatr Endocrinol Metab; 2002 Feb; 15(2):163-74. PubMed ID: 11874181
[TBL] [Abstract][Full Text] [Related]
22. Interventions for Improving Bone Mineral Density and Reducing Fracture Risk in Osteogenesis Imperfecta: A Mixed Treatment Comparison Network Meta-analysis of Randomized Controlled Clinical Trials.
Sridharan K; Sivaramakrishnan G
Curr Clin Pharmacol; 2018; 13(3):190-198. PubMed ID: 30160216
[TBL] [Abstract][Full Text] [Related]
23. Oral bisphosphonate treatment for osteogenesis imperfecta--an Indian perspective.
Shah I; Johari A
Ann Trop Paediatr; 2007 Mar; 27(1):39-43. PubMed ID: 17469731
[TBL] [Abstract][Full Text] [Related]
24. Osteogenesis imperfecta: anthropometric, skeletal and mineral metabolic effects of long-term intravenous pamidronate therapy.
Vallo A; Rodriguez-Leyva F; Rodríguez Soriano J
Acta Paediatr; 2006 Mar; 95(3):332-9. PubMed ID: 16497645
[TBL] [Abstract][Full Text] [Related]
25. Low-dose intravenous pamidronate treatment in osteogenesis imperfecta.
Gökşen D; Coker M; Darcan S; Köse T; Kara S
Turk J Pediatr; 2006; 48(2):124-9. PubMed ID: 16848111
[TBL] [Abstract][Full Text] [Related]
26. Osteogenesis imperfecta type VI in childhood and adolescence: effects of cyclical intravenous pamidronate treatment.
Land C; Rauch F; Travers R; Glorieux FH
Bone; 2007 Mar; 40(3):638-44. PubMed ID: 17127117
[TBL] [Abstract][Full Text] [Related]
27. Intravenous Bisphosphonate Therapy of Young Children With Osteogenesis Imperfecta: Skeletal Findings During Follow Up Throughout the Growing Years.
Palomo T; Fassier F; Ouellet J; Sato A; Montpetit K; Glorieux FH; Rauch F
J Bone Miner Res; 2015 Dec; 30(12):2150-7. PubMed ID: 26059976
[TBL] [Abstract][Full Text] [Related]
28. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta.
Glorieux FH; Bishop NJ; Plotkin H; Chabot G; Lanoue G; Travers R
N Engl J Med; 1998 Oct; 339(14):947-52. PubMed ID: 9753709
[TBL] [Abstract][Full Text] [Related]
29. Pamidronate in children and adolescents with osteogenesis imperfecta: effect of treatment discontinuation.
Rauch F; Munns C; Land C; Glorieux FH
J Clin Endocrinol Metab; 2006 Apr; 91(4):1268-74. PubMed ID: 16434452
[TBL] [Abstract][Full Text] [Related]
30. Impact of alendronate on quality of life in children with osteogenesis imperfecta.
Seikaly MG; Kopanati S; Salhab N; Waber P; Patterson D; Browne R; Herring JA
J Pediatr Orthop; 2005; 25(6):786-91. PubMed ID: 16294137
[TBL] [Abstract][Full Text] [Related]
31. Beneficial effects of intravenous pamidronate treatment in children with osteogenesis imperfecta under 24 months of age.
Kusumi K; Ayoob R; Bowden SA; Ingraham S; Mahan JD
J Bone Miner Metab; 2015 Sep; 33(5):560-8. PubMed ID: 25319557
[TBL] [Abstract][Full Text] [Related]
32. Effects of oral alendronate on BMD in adult patients with osteogenesis imperfecta: a 3-year randomized placebo-controlled trial.
Chevrel G; Schott AM; Fontanges E; Charrin JE; Lina-Granade G; Duboeuf F; Garnero P; Arlot M; Raynal C; Meunier PJ
J Bone Miner Res; 2006 Feb; 21(2):300-6. PubMed ID: 16418786
[TBL] [Abstract][Full Text] [Related]
33. Efficacy of oral alendronate in children with osteogenesis imperfecta.
Cho TJ; Choi IH; Chung CY; Yoo WJ; Park MS; Park YK
J Pediatr Orthop; 2005; 25(5):607-12. PubMed ID: 16199940
[TBL] [Abstract][Full Text] [Related]
34. Experience with bisphosphonates in osteogenesis imperfecta.
Glorieux FH
Pediatrics; 2007 Mar; 119 Suppl 2():S163-5. PubMed ID: 17332237
[TBL] [Abstract][Full Text] [Related]
35. Intravenous pamidronate treatment in osteogenesis imperfecta.
Bembi B; Parma A; Bottega M; Ceschel S; Zanatta M; Martini C; Ciana G
J Pediatr; 1997 Oct; 131(4):622-5. PubMed ID: 9386671
[TBL] [Abstract][Full Text] [Related]
36. Successful results of pamidronate treatment in children with osteogenesis imperfecta with emphasis on the interpretation of bone mineral density for local standards.
Poyrazoglu S; Gunoz H; Darendeliler F; Bas F; Tutunculer F; Eryilmaz SK; Bundak R; Saka N
J Pediatr Orthop; 2008 Jun; 28(4):483-7. PubMed ID: 18520289
[TBL] [Abstract][Full Text] [Related]
37. Safety and efficacy of a 1-year treatment with zoledronic acid compared with pamidronate in children with osteogenesis imperfecta.
Barros ER; Saraiva GL; de Oliveira TP; Lazaretti-Castro M
J Pediatr Endocrinol Metab; 2012; 25(5-6):485-91. PubMed ID: 22876543
[TBL] [Abstract][Full Text] [Related]
38. Intravenous pamidronate treatment in children with moderate to severe osteogenesis imperfecta: assessment of indices of dual-energy X-ray absorptiometry and bone metabolic markers during the first year of therapy.
Arikoski P; Silverwood B; Tillmann V; Bishop NJ
Bone; 2004 Mar; 34(3):539-46. PubMed ID: 15003801
[TBL] [Abstract][Full Text] [Related]
39. Effect of alendronate therapy in children with osteogenesis imperfecta.
Vyskocil V; Pikner R; Kutílek S
Joint Bone Spine; 2005 Oct; 72(5):416-23. PubMed ID: 16214075
[TBL] [Abstract][Full Text] [Related]
40. Treatment of children with Osteogenesis imperfecta in Estonia.
Maasalu K; Haviko T; Märtson A
Acta Paediatr; 2003 Apr; 92(4):452-5. PubMed ID: 12801112
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]